
#### American Society of Hematology Annual Meeting

**ASH** 

Atlanta, GA, USA and Virtual December 11-14, 2021





You are entering a medical section of the Pfizer Landing Page. All materials presented here are for purposes of scientific exchange. They are NOT presented for any promotional purpose

#### **Pfizer Oral Presentations**

Oral presentations will be presented in Eastern Standard Time (EST).

### Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Immune Therapy for Multiple Myeloma

Monday, December 13

6:15 PM - 7:45 PM

Room A411-A412

**Elranatamab** 

Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: Results from MagnetisMM-1

Sebag M

**View Presentation** 

#### **Pfizer Poster Presentations**

ASH Poster Presentations will be available for viewing in Hall B5 of the Georgia World Congress Center (Atlanta, GA) and virtually.

#### Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I

Saturday, December 11

5:30 PM - 7:30 PM

Inotuzumab 1208

The efficacy and safety of low-dose inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia: interim results of a phase 4 study Ozcan M

**View Presentation** 

#### Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I

Saturday, December 11

5:30 PM - 7:30 PM

**Bosutinib** 1475

Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial

Gambacorti-Passerini C

View Presentation

# Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective

Saturday, December 11

Therapeutic Trials: Poster I

5:30 PM - 7:30 PM

**Elranatamab** 1674

MagnetisMM-3: an open-label, multicenter, nonrandomized phase 2 study of elranatamab (PF-06863135) in patients with relapsed or refractory multiple myeloma Lesokhin A

View Presentation

### Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II

Sunday, December 12

6:00 PM - 8:00 PM

Hall B5

**Bosutinib** 

2557

Efficacy and safety of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: final 3-year results of a phase 2 study Ono T

**View Presentation** 

## Health Services Research—Lymphoid Malignancies: Poster II

Sunday, December 12 6:00 PM - 8:00 PM

Inotuzumab

3012

A pilot study of the application of natural language understanding to identify insights on acute lymphocytic leukemia and its treatment from social media data Crawford R

View Presentation

View additional Pfizer congress materials: